益生菌作为抑郁症辅助治疗的可接受性、耐受性及推定疗效估计:一项随机临床试验
这项单中心、双盲、安慰剂对照预试验纳入50例抗抑郁药应答不充分的重性抑郁障碍成人,随机接受多菌株益生菌(每日80亿CFU)或安慰剂8周辅助治疗。结果显示脱落率8%、依从性97.2%、无严重不良反应,益生菌组HAMD-17和IDS自评及HAMA焦虑症状改善优于安慰剂组,但GAD-7差异不显著。
要点
- 益生菌辅助治疗8周耐受性良好,脱落率8%,依从性97.2%,无严重不良反应。
- 益生菌组HAMD-17第4周效应量0.70(95%CI 0.01-0.98),IDS自评第8周0.64(95%CI 0.03-0.87)。
- HAMA第4周效应量0.67(95%CI 0-0.95),第8周0.79(95%CI 0.06-1.05);GAD-7差异不显著。
核心结论
- 益生菌作为重性抑郁障碍辅助治疗的可接受性、耐受性和对关键临床结局的估计效应量令人鼓舞,支持进一步开展确证性疗效试验。
研究设计与样本
- 单中心、双盲、安慰剂对照预试验随机临床试验,纳入18至55岁、正在服用抗抑郁药但应答不充分的重性抑郁障碍成人,从伦敦初级和二级保健服务及普通广告招募,数据收集于2019年9月至2022年5月。
- 共纳入50例参与者,49例接受干预并纳入意向性分析,其中39例(80%)为女性,平均(SD)年龄31.7(9.8)岁;24例随机分配至益生菌组,25例至安慰剂组。
- 干预为多菌株益生菌(每日80亿菌落形成单位)或安慰剂,每日一次,共8周,叠加于正在进行的抗抑郁药治疗。
主要发现
- 脱落率为8%(益生菌组1例,安慰剂组3例),依从性97.2%,无严重不良反应。
- 益生菌组第4周和第8周HAMD-17平均(SD)评分分别为11.00(5.13)和8.83(4.28),IDS分别为30.17(11.98)和25.04(11.68),HAMA分别为11.71(5.86)和8.17(4.68),GAD-7分别为7.78(4.12)和7.63(4.77)。
- 安慰剂组第4周和第8周HAMD-17平均(SD)评分分别为14.04(3.70)和11.09(3.22),IDS分别为33.82(9.26)和29.64(9.31),HAMA分别为14.70(5.47)和10.95(4.48),GAD-7分别为10.91(5.32)和9.48(5.18)。
- 线性混合模型标准化效应量显示,益生菌组HAMD-17第4周SES为0.70(95%CI 0.01-0.98),IDS自评第8周SES为0.64(95%CI 0.03-0.87),HAMA第4周SES为0.67(95%CI 0-0.95)、第8周SES为0.79(95%CI 0.06-1.05),均优于安慰剂组;GAD-7第4周SES为0.57(95%CI -0.01至0.82)、第8周SES为0.32(95%CI -0.19至0.65),差异不显著。
关键数值与推荐
- 预试验主要结局为保留率、可接受性、耐受性及推定治疗效应估计,用于确证性试验的指标。
- 抑郁症状评估采用HAMD-17和IDS,焦虑症状评估采用HAMA和GAD-7。
临床怎么用
- 对于抗抑郁药应答不充分的重性抑郁障碍患者,益生菌辅助治疗8周表现出良好耐受性和依从性,可作为未来确证性试验的候选辅助策略。
- 临床决策应等待确证性疗效试验结果,当前证据尚不足以常规推荐益生菌辅助治疗。
局限性
- 本研究为单中心预试验,样本量小(49例纳入分析),旨在估计效应量和可行性,非确证性疗效试验。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The microbiota-gut-brain axis is a promising target for novel treatments for mood disorders, such as probiotics. However, few clinical trials have been conducted, and further safety and efficacy data are needed to support this treatment approach. OBJECTIVE: To provide acceptability and tolerability data and estimates of intervention effect size for probiotics as adjunctive treatment for patients with major depressive disorder (MDD). DESIGN, SETTING, AND PARTICIPANTS: In this single-center, double-blind, placebo-controlled pilot randomized clinical trial, adults aged 18 to 55 years with MDD taking antidepressant medication but having an incomplete response were studied. A random sample was recruited from primary and secondary care services and general advertising in London, United Kingdom. Data were collected between September 2019 and May 2022 and analyzed between July and September 2022. INTERVENTION: Multistrain probiotic (8 billion colony-forming units per day) or placebo daily for 8 weeks added to ongoing antidepressant medication. MAIN OUTCOMES AND MEASURES: The pilot outcomes of the trial were retention, acceptability, tolerability, and estimates of putative treatment effect on clinical symptoms (depression: Hamilton Depression Rating Scale [HAMD-17] and Inventory of Depressive Symptomatology [IDS] scores; anxiety: Hamilton Anxiety Rating Scale [HAMA] and General Anxiety Disorder [GAD-7] scores) to be used as indicators for a definitive trial. RESULTS: Of 50 included participants, 49 received the intervention and were included in intent-to-treat analyses; of these, 39 (80%) were female, and the mean (SD) age was 31.7 (9.8) years. A total of 24 were randomized to probiotic and 25 to placebo. Attrition was 8% (1 in the probiotic group and 3 in the placebo group), adherence was 97.2%, and there were no serious adverse reactions. For the probiotic group, mean (SD) HAMD-17 scores at weeks 4 and 8 were 11.00 (5.13) and 8.83 (4.28), respectively; IDS, 30.17 (11.98) and 25.04 (11.68); HAMA, 11.71 (5.86) and 8.17 (4.68); and GAD-7, 7.78 (4.12) and 7.63 (4.77). For the placebo group, mean (SD) HAMD-17 scores at weeks 4 and 8 were 14.04 (3.70) and 11.09 (3.22), respectively; IDS, 33.82 (9.26) and 29.64 (9.31); HAMA, 14.70 (5.47) and 10.95 (4.48); and GAD-7, 10.91 (5.32) and 9.48 (5.18). Standardized effect sizes (SES) from linear mixed models demonstrated that the probiotic group attained greater improvements in depressive symptoms according to HAMD-17 scores (week 4: SES, 0.70; 95% CI, 0.01-0.98) and IDS Self Report scores (week 8: SES, 0.64; 95% CI, 0.03-0.87) as well as greater improvements in anxiety symptoms according to HAMA scores (week 4: SES, 0.67; 95% CI, 0-0.95; week 8: SES, 0.79; 95% CI, 0.06-1.05), but not GAD-7 scores (week 4: SES, 0.57; 95% CI, -0.01 to 0.82; week 8: SES, 0.32; 95% CI, -0.19 to 0.65), compared with the placebo group. CONCLUSIONS AND RELEVANCE: The acceptability, tolerability, and estimated effect sizes on key clinical outcomes are promising and encourage further investigation of probiotics as add-on treatment for people with MDD in a definitive efficacy trial. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03893162.
引用
- Nikolova VL, Cleare AJ, Young AH, et al. Acceptability, Tolerability, and Estimates of Putative Treatment Effects of Probiotics as Adjunctive Treatment in Patients With Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2023. PMID: 37314797. doi:10.1001/jamapsychiatry.2023.1817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。